Zacks Investment Research
03 Sept 2026, 16:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Krystal Biotech's Vyjuvek therapy generated $119.2 million in Q2 2026 global net product revenues, a 24% year-over-year increase. — Strong revenue growth and a 95% gross margin indicate high profitability and commercial viability for the company's primary product.
+0.60Krystal Biotech is advancing a diversified pipeline of genetic medicines for respiratory, ophthalmology, oncology, and aesthetics indications. — Expanding from a single-product to a multi-product company reduces concentration risk and opens new growth verticals.
+0.40Krystal expects to release interim study data for its KB407 cystic fibrosis program by the end of the year. — Upcoming clinical data acts as a near-term catalyst that could significantly move the stock depending on the results.
+0.30Continue reading
6 related stories
Search tags
The company targets commercial launches for Vyjuvek in Italy and Spain by the end of 2026. — Expanding the geographic footprint into new European markets provides a clear path for incremental revenue growth.
+0.20Which stocks this story touches
Strong stock growth, improving investor confidence, and positive revenue and margin performance for Vyjuvek.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
7h ago
